Logo image of GENI

GENIUS SPORTS LTD (GENI) Stock Fundamental Analysis

NYSE:GENI - New York Stock Exchange, Inc. - GG00BMF1JR16 - Common Stock - Currency: USD

12.52  +0.13 (+1.05%)

After market: 12.49 -0.03 (-0.24%)

Fundamental Rating

4

Taking everything into account, GENI scores 4 out of 10 in our fundamental rating. GENI was compared to 131 industry peers in the Hotels, Restaurants & Leisure industry. No worries on liquidiy or solvency for GENI as it has an excellent financial health rating, but there are worries on the profitability. GENI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GENI had negative earnings in the past year.
GENI had a positive operating cash flow in the past year.
In the past 5 years GENI always reported negative net income.
In multiple years GENI reported negative operating cash flow during the last 5 years.
GENI Yearly Net Income VS EBIT VS OCF VS FCFGENI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -8.39%, GENI is not doing good in the industry: 83.21% of the companies in the same industry are doing better.
GENI has a Return On Equity of -10.81%. This is comparable to the rest of the industry: GENI outperforms 45.04% of its industry peers.
Industry RankSector Rank
ROA -8.39%
ROE -10.81%
ROIC N/A
ROA(3y)-14.16%
ROA(5y)-22.16%
ROE(3y)-19.14%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
GENI Yearly ROA, ROE, ROICGENI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 23.57%, GENI is doing worse than 82.44% of the companies in the same industry.
GENI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GENI Yearly Profit, Operating, Gross MarginsGENI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

8

2. Health

2.1 Basic Checks

GENI does not have a ROIC to compare to the WACC, probably because it is not profitable.
GENI has more shares outstanding than it did 1 year ago.
GENI has a better debt/assets ratio than last year.
GENI Yearly Shares OutstandingGENI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M 200M
GENI Yearly Total Debt VS Total AssetsGENI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

GENI has an Altman-Z score of 7.77. This indicates that GENI is financially healthy and has little risk of bankruptcy at the moment.
GENI has a better Altman-Z score (7.77) than 89.31% of its industry peers.
GENI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.77
ROIC/WACCN/A
WACC9.18%
GENI Yearly LT Debt VS Equity VS FCFGENI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.36 indicates that GENI has no problem at all paying its short term obligations.
GENI has a better Current ratio (2.36) than 88.55% of its industry peers.
A Quick Ratio of 2.36 indicates that GENI has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.36, GENI belongs to the best of the industry, outperforming 90.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2.36
GENI Yearly Current Assets VS Current LiabilitesGENI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.42% over the past year.
The Revenue has grown by 25.76% in the past year. This is a very strong growth!
Measured over the past years, GENI shows a very strong growth in Revenue. The Revenue has been growing by 24.82% on average per year.
EPS 1Y (TTM)18.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)25.76%
Revenue growth 3Y24.82%
Revenue growth 5YN/A
Sales Q2Q%24.38%

3.2 Future

Based on estimates for the next years, GENI will show a very strong growth in Earnings Per Share. The EPS will grow by 43.36% on average per year.
GENI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.58% yearly.
EPS Next Y89.99%
EPS Next 2Y56.15%
EPS Next 3Y43.36%
EPS Next 5YN/A
Revenue Next Year21.45%
Revenue Next 2Y18.7%
Revenue Next 3Y17.99%
Revenue Next 5Y15.58%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GENI Yearly Revenue VS EstimatesGENI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
GENI Yearly EPS VS EstimatesGENI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GENI. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 105.81 indicates a quite expensive valuation of GENI.
67.18% of the companies in the same industry are cheaper than GENI, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 33.87, GENI is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 105.81
GENI Price Earnings VS Forward Price EarningsGENI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GENI Per share dataGENI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as GENI's earnings are expected to grow with 43.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.15%
EPS Next 3Y43.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GENI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENIUS SPORTS LTD

NYSE:GENI (8/11/2025, 8:04:01 PM)

After market: 12.49 -0.03 (-0.24%)

12.52

+0.13 (+1.05%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners92.2%
Inst Owner Change3.81%
Ins Owners8.64%
Ins Owner ChangeN/A
Market Cap3.15B
Analysts83.33
Price Target13.37 (6.79%)
Short Float %13.39%
Short Ratio6.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-581.75%
Min EPS beat(2)-1186.76%
Max EPS beat(2)23.27%
EPS beat(4)2
Avg EPS beat(4)-403.96%
Min EPS beat(4)-1186.76%
Max EPS beat(4)564.64%
EPS beat(8)2
Avg EPS beat(8)-245.45%
EPS beat(12)3
Avg EPS beat(12)-199.81%
EPS beat(16)4
Avg EPS beat(16)-161.92%
Revenue beat(2)0
Avg Revenue beat(2)-1.88%
Min Revenue beat(2)-2.01%
Max Revenue beat(2)-1.76%
Revenue beat(4)0
Avg Revenue beat(4)-1.67%
Min Revenue beat(4)-2.01%
Max Revenue beat(4)-0.92%
Revenue beat(8)1
Avg Revenue beat(8)-1.09%
Revenue beat(12)3
Avg Revenue beat(12)-0.04%
Revenue beat(16)7
Avg Revenue beat(16)1.52%
PT rev (1m)5.42%
PT rev (3m)8.36%
EPS NQ rev (1m)-4.37%
EPS NQ rev (3m)-293.47%
EPS NY rev (1m)0%
EPS NY rev (3m)-151.6%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)0.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 105.81
P/S 5.64
P/FCF N/A
P/OCF 59.07
P/B 4.37
P/tB 11.33
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.12
Fwd EY0.95%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)0.21
OCFY1.69%
SpS2.22
BVpS2.86
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.39%
ROE -10.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.57%
FCFM N/A
ROA(3y)-14.16%
ROA(5y)-22.16%
ROE(3y)-19.14%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 117.79%
Cap/Sales 13.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.36
Quick Ratio 2.36
Altman-Z 7.77
F-Score6
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)73.83%
Cap/Depr(5y)N/A
Cap/Sales(3y)12.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next Y89.99%
EPS Next 2Y56.15%
EPS Next 3Y43.36%
EPS Next 5YN/A
Revenue 1Y (TTM)25.76%
Revenue growth 3Y24.82%
Revenue growth 5YN/A
Sales Q2Q%24.38%
Revenue Next Year21.45%
Revenue Next 2Y18.7%
Revenue Next 3Y17.99%
Revenue Next 5Y15.58%
EBIT growth 1Y-30.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year363.54%
EBIT Next 3Y86.23%
EBIT Next 5Y53.48%
FCF growth 1Y71.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y322.19%
OCF growth 3YN/A
OCF growth 5YN/A